|
V940 Clinical Trials
2 actively recruiting trials across 2 locations
No change since May 2026
Also known as: Intismeran Autogene, mRNA-4157
Pipeline
Phase 2: 2
Top Sponsors
- Merck Sharp & Dohme LLC2
Indications
- Cancer2
- Squamous Non-small-cell Lung Cancer1
- Malignant Melanoma1
- Lung Cancer1
Springdale, Arkansas1 trial
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Highlands Oncology Group ( Site 4042)
Phase 2
Tampa, Florida1 trial
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Moffitt Cancer Center ( Site 0021)
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.